If you have been reading about Reversed-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
The BSE SENSEX (also known as the S&P Bombay Stock Exchange Sensitive Index or simply SENSEX) is an Indian free-float market-weighted stock market index of 30 well-established and financially sound companies listed on the Bombay Stock Exchange. The 30 constituent companies which are some of the largest and most actively traded stocks, are representative of various industrial sectors of the Indian economy. Published since 1 January 1986, the S&P BSE SENSEX is regarded as the pulse of the domestic stock markets in India. The base value of the SENSEX was taken as 100 on 1 April 1979 and its base year as 1978–79. On 25 July 2001, BSE launched DOLLEX-, a dollar-linked version of the SENSEX.
Metalloprotein is a generic term for a protein that contains a metal ion cofactor. A large proportion of all proteins are part of this category. For instance, at least 1000 human proteins (out of ~20,000) contain zinc-binding protein domains although there may be up to 3000 human zinc metalloproteins.
The same procedure was followed as in Annis, but the sample of galaxies used is 80 times larger than that used in the Annis study. Some sources were classified as "lopsided": they appear asymmetric in shape, meaning that one side of the galactic disc is more massive and less luminous than the other. This characteristic, according to Calissendorff, could be an indication that the galaxy is home to a civilization that has placed Dyson spheres in its main part. This can be explained by the fact that the colonization starts from one side of the galactic disk, making it appear darker and leading a distant observer to believe that the core has moved to that same side. On the other hand, a galaxy hosting Dyson spheres should be characterized by a significant source of far-infrared radiation. The fact remains that a Type III civilization can consume energy through a Dyson sphere without surrounding a star. Indeed, such megastructures could also extract energy from a black hole, according to the study by Inoue and Yokoo (2011). However, such a structure would not reduce the luminosity of an observed galaxy. Calissendorff's study concludes that 11 of the sources analyzed (out of a catalog of 2,411 galaxies, or 0.46%) show possible evidence of a Type III civilization. Searching for objects that obscure 90% of the light leaves only one source remains that meets the criteria. These positive sources show a low redshift (so they are old, about 100 million years), which is consistent with possible Type III civilizations, that could have flourished only in the early past.
Diffuse connective tissue diseases Rheumatoid arthritis Juvenile arthritis Systemic lupus erythematosus Sjögren syndrome Scleroderma Polymyositis Dermatomyositis Behçet's disease Relapsing polychondritis Arthritis associated with spondylitis (i.e. spondarthritis) Ankylosing spondylitis Reactive arthritis Psoriatic arthritis Osteoarthritis (i.e. osteoarthrosis, degenerative joint disease) Rheumatic syndromes associated with infectious agents (direct and indirect or reactive) Metabolic and endocrine diseases associated with rheumatic states Gout, pseudogout Neoplasms Neurovascular disorders Bone and cartilage disorders Extraarticular disorders Bursitis/Tendinitis of the shoulder, wrist, biceps, leg, knee cap (patella), ankle, hip, and Achilles tendon Capsulitis Miscellaneous disorders associated with articular manifestations Palindromic rheumatism is thought to be a form of rheumatoid arthritis.
Einsteinium at The Periodic Table of Videos (University of Nottingham) Age-related factors in radionuclide metabolism and dosimetry: Proceedings – contains several health related studies of einsteinium
Sources: en.wikipedia.org
== Structure == MHC class I molecules are heterodimers that consist of two polypeptide chains, α and β2-microglobulin (B2M). The two chains are linked noncovalently via interaction of B2M and the α3 domain. Only the α chain is polymorphic and encoded by a HLA gene, while the B2M subunit is not polymorphic and encoded by the beta-2 microglobulin gene. The α3 domain is plasma membrane-spanning and interacts with the CD8 co-receptor of T-cells. The α3-CD8 interaction holds the MHC I molecule in place while the T cell receptor (TCR) on the surface of the cytotoxic T cell binds its α1-α2 heterodimer ligand, and checks the coupled peptide for antigenicity. The α1 and α2 domains fold to make up a groove for peptides to bind. MHC class I molecules bind peptides that are predominantly 8-10 amino acid in length (Parham 87), but the binding of longer peptides have also been reported. While a high-affinity peptide and the B2M subunit are normally required to maintain a stable ternary complex between the peptide, MHC I, and B2M, under subphysiological temperatures, stable, peptide-deficient MHC I/B2M heterodimers have been observed. Synthetic stable, peptide-receptive MHC I molecules have been generated using a disulfide bond between the MHC I and B2M, named "open MHC-I".
=== Phase 2 === BAER-101 (AZ-7325; AZD-7325) – selective GABAA α2 and α3 subunit-containing receptor positive allosteric modulator and nonbenzodiazepine/cinnoline Brexanolone caprilcerbate (Glyph Allopregnanolone; GlyphAllo; LYT-300; SPT-300; allopregnanolone prodrug) – GABAA receptor positive allosteric modulator and neurosteroid (brexanolone prodrug) [4] Cannabidiol (CBD; Arvisol) – cannabinoid receptor modulator and other actions [5] Cenobamate (ONO-2017; Ontozry; X-Copri; Xcopri; YKP-3089) – atypical voltage-gated sodium channel blocker and GABAA receptor positive allosteric modulator [6] ENX-102 (ENX102) — α2, α3, and α5 subunit-containing GABAA receptor positive allosteric modulator and nonbenzodiazepine JNJ-42165279 (JNJ-5279) – fatty acid amide hydrolase (FAAH) inhibitor [7] Maritupirdine (CD-008-0045) – serotonin 5-HT6 receptor antagonist [8] Psilocybin low dose (APEX-52) – non-selective serotonin receptor agonist and psychedelic hallucinogen [9] Vortioxetine (Brintellix; Lu-AA21004; trintellix; Vortidif) – serotonin reuptake inhibitor, serotonin 5-HT1A and 5-HT1B receptor agonist, and serotonin 5-HT1D, 5-HT3, and 5-HT7 receptor antagonist [10] Zuranolone (BIIB-125; S-812217; SAGE-217; SGE-797; Zurzuvae) – GABAA receptor positive allosteric modulator and neurosteroid [11]
Gene expression in mammals is regulated by many cis-regulatory elements, including core promoters and promoter-proximal elements that are located near the transcription start sites of genes, upstream on the DNA (towards the 5' region of the sense strand). Other important cis-regulatory modules are localized in DNA regions that are distant from the transcription start sites. These include enhancers, silencers, insulators and tethering elements. Enhancers and their associated transcription factors have a leading role in the regulation of gene expression. Enhancers are genome regions that regulate genes. Enhancers control cell-type-specific gene expression programs, most often by looping through long distances to come in physical proximity with the promoters of their target genes. Multiple enhancers, each often tens or hundred of thousands of nucleotides distant from their target genes, loop to their target gene promoters and coordinate with each other to control gene expression. The illustration shows an enhancer looping around to come into proximity with the promoter of a target gene. The loop is stabilized by a dimer of a connector protein (e.g. dimer of CTCF or YY1). One member of the dimer is anchored to its binding motif on the enhancer and the other member is anchored to its binding motif on the promoter (represented by the red zigzags in the illustration). Several cell function-specific transcription factors (among the about 1,600 transcription factors in a human cell) generally bind to specific motifs on an enhancer.
=== Religious beliefs === De Duve was brought up as a Roman Catholic. In his later years he tended towards agnosticism, if not strict atheism. However, de Duve believed that "Most biologists, today, tend to see life and mind as cosmic imperatives, written into the very fabric of the universe, rather than as extraordinarily improbable products of chance." "It would be an exaggeration to say I'm not afraid of death", he explicitly said to a Belgian newspaper Le Soir just a month before his death, "but I'm not afraid of what comes after, because I'm not a believer." He strongly supported biological evolution as a fact, and dismissive of creation science and intelligent design, as explicitly stated in one of his last books, Genetics of Original Sin: The Impact of Natural Selection on the Future of Humanity (French original 2009). He was among the seventy-eight Nobel laureates in science to endorse the effort to repeal the Louisiana Science Education Act of 2008.
The enzyme belongs to the family of transferases, to be specific those acyltransferases transferring groups other than aminoacyl groups. The systematic name of this enzyme class is malonyl-CoA:4-coumaroyl-CoA malonyltransferase (cyclizing, reducing).
Sources: en.wikipedia.org
==== Magnetic drug delivery ==== Magnetic nanochains are a class of new magnetoresponsive and superparamagnetic nanostructures with highly anisotropic shapes (chain-like) which can be manipulated using magnetic field and magnetic field gradient. The magnetic nanochains possess attractive properties which are significant added value for many potential uses including magneto-mechanical actuation-associated nanomedicines in low and super-low frequency alternating magnetic field and magnetic drug delivery. Cell imaging Nanoparticles have good biological labeling and sensing because of brightness and photostability; thus, certain self-assembled nanoparticles can be used as imaging contrast in various systems. Combined with polymer cross-linkers, the fluorescence intensity can also be enhanced. Surface modification with functional groups, can also lead to selective biological labeling. Self-assembled nanoparticles are also more biocompatible compared to standard drug delivery systems.
== Enzyme mechanism == Cystathionase uses pyridoxal phosphate to facilitate the cleavage of the sulfur-gamma carbon bond of cystathionine, resulting in the release of cysteine. The lysine residue reforms the internal aldimine by kicking off α-iminobutyric acid. Afterwards the external ketimine is hydrolyzed, causing the formation of α-ketobutyrate. The amino group on cystathionine is deprotonated and undergoes a nucleophilic attack of the internal aldimine. An additional deprotonation by a general base results in the formation of the external aldimine and removal of the lysine residue. The basic lysine residue is then able to deprotonate the alpha carbon, pushing electron density into the nitrogen of the pyridine ring. Pyridoxal phosphate is necessary to stabilize this carbanionic intermediate; otherwise the proton's pKa would be too high. The beta carbon is then deprotonated, creating an alpha-beta unsaturation and pushing a lone pair onto the aldimine nitrogen. To reform the aldimine, this lone pair pushes back down, cleaving the sulfur-gamma carbon bond, resulting in the release of cysteine. A pyridoxamine derivative of vinyl glyoxylate remains after the gamma elimination. The lone pair from the pyridine nitrogen pushes electron density to the gamma carbon, which is protonated by lysine. Lysine then attacks the external aldimine, pushing electron density to the beta carbon, which is protonated by a general acid. The imine is then hydrolyzed to release α-ketobutyrate. Deprotonation of the lysine residue causes ammonia to leave, thus completing the catalytic cycle.
Meclizine is an international nonproprietary name. It is sold under the brand names Bonine, Bonamine, Antivert, Postafen, Sea Legs, and Dramamine II (Less Drowsy Formulation). Emesafene is a combination of meclizine (1/3) and pyridoxine (2/3). In Canada, Antivert Tab was a combination of meclizine and nicotinic acid.
One way to effectively deal with the inherent multi-physics and the control systems development that is involved when including intelligent systems, is to adopt the V-Model approach to systems development, as has been widely used in the automotive industry for twenty years or more. In this V-approach, system-level requirements are propagated down the V via subsystems to component design, and the system performance is validated at increasing integration levels. Engineering of mechatronic systems requires the application of two interconnected "V-cycles": one focusing on the multi-physics system engineering (like the mechanical and electrical components of an electrically powered steering system, including sensors and actuators); and the other focuses on the controls engineering, the control logic, the software and realization of the control hardware and embedded software.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
Mass spectrometry establishes whether the observed molecular weight matches the calculated sequence mass. Chromatographic retention and fragment mapping add further confidence about sequence and composition. A single technique alone is rarely treated as sufficient evidence of identity.